Overview
- The CDC reports more than 7,000 U.S. cases in 2025, with health officials confirming spread in hospitals and nursing homes in New York and New Jersey.
- Experts say the yeast colonizes skin and lingers on bedrails, catheters, and other equipment, allowing asymptomatic carriers to drive extensive transmission.
- Many strains resist azoles and clinicians rely on echinocandins as first-line therapy, yet resistance is appearing in clusters and can leave few effective options.
- Early cases were frequently misidentified, and hospitals now use MALDI-TOF or PCR with admission screening to rapidly isolate patients and enforce targeted cleaning.
- The treatment pipeline is advancing, with once-weekly rezafungin approved for invasive candidiasis and ibrexafungerp and fosmanogepix in trials showing activity against C. auris.